Pla2g2f Gene Delivery Vectors for Neuroinflammation and Memory Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and Amyotrophic Lateral Sclerosis are inadequate, and there is a need for better therapies to address neuroinflammation, cognitive decline, and memory loss.

Innovation Solution

Administering a vector encoding phospholipase A2 group IIF (Pla2g2f) to increase its expression in cells, using methods like adeno-associated virus (AAV) or lentiviral vectors, to enhance cognitive function, delay cognitive decline, and improve memory.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for neurodegenerative disorders are used, then existing therapeutic options are available, but treatment effectiveness is inadequate

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidcognitive function

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses viral vectors (AAV or lentiviral vectors) as intermediaries to deliver the Pla2g2f gene into target cells. This intermediary approach enables effective treatment by bridging the gap between the therapeutic gene and the target cells, achieving reliable treatment effectiveness that current direct treatments cannot provide

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the expression level parameter of Pla2g2f by administering vectors that increase its expression. This parameter change from baseline to elevated levels produces therapeutic effects that improve treatment effectiveness and cognitive function simultaneously

Inventive Principle:

Principle #35Parameter changes

2Productivity

If Pla2g2f expression is increased to improve cognitive function, then cognitive function is enhanced and memory is improved, but neuroinflammation and microglia reactivity must be controlled

Engineering Contradiction:

Improvecognitive functionVSAvoidneuroinflammation

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the potentially harmful effect of increased microglia and astrocyte reactivity into a beneficial outcome by carefully controlling Pla2g2f expression levels. The controlled expression enhances cognitive function while the reactive microglia and astrocytes are harnessed to clear amyloid plaques and support synapse maintenance, transforming neuroinflammation from harmful to beneficial

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If vectors are administered to increase Pla2g2f expression, then treatment of neurodegeneration is achieved, but delivery precision to target cells must be ensured

Engineering Contradiction:

Improvetreatment efficacyVSAvoidvector delivery precision

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent employs viral vectors as intermediary delivery systems that naturally target and infect specific cell types. These vectors act as precise mediators that deliver the Pla2g2f gene to the correct target cells with high precision, overcoming the challenge of achieving accurate delivery without complex external targeting mechanisms

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250235513A1Vectors and methods for the treatment of neurodegeneration, delaying cognitive decline, and improving memory

Publication Date: 2025.07.24 THE GENERAL HOSPITAL CORP

AI summary

The present invention relates to treating neurodegeneration (e.g., a neurodegenerative disorder), enhancing cognitive function, delaying or reducing cognitive decline, enhancing the metabolism, and/or improving memory in patients in need thereof, e.g., patients diagnosed with a neurodegenerative disorder or displaying one or more symptoms of a neurodegenerative disorder (e.g., declining cognitive function) by administering Pla2g2f to a subject or increasing expression of Pla2g2f in a cell of a subject.